https://nec-1sinhibitor.com/ch....olinergic-and-also-i
In terms of overall survival, the lenvatinib plus pembrolizumab group's median follow-up period was 337 months (IQR 274-369), while the sunitinib group's was 334 months (IQR 267-368). Compared to sunitinib, lenvatinib plus pembrolizumab demonstrated improved overall survival, with median survival times not reaching a specific point (95% CI 415-not estimable for lenvatinib/pembrolizumab, and 95% C
Respect!
Kommentar
Delen
